James Hawkins (Insider Trades), president and CEO of Natus Medical Inc. (BABY), acquired 10,000 shares in the company on Sept. 28. The price per share was $38.48 for a total transaction of $384,800.
Natus Medical provides health care products and services used for screening, detection, treatment, monitoring and tracking of common medical ailments in neurological dysfunction, epilepsy, sleep disorders, newborn care, hearing impairment and balance and mobility disorders. The company has a market cap of $1.27 billion.
There were a total of 15,000 Natus Medical shares purchased in two insider transactions to date since 2013. Including the aforementioned transaction, Hawkins acquired 20,000 shares in the company since 2012 and sold 987,024 shares in 11 transactions since then. Hawkins’ most recent transaction is the first insider purchase since 2013. Natus Medical's number of insider sells increased each year from 14 transactions totaling 398,406 shares in 2013 to 23 transactions totaling 645,505 shares in 2015. For more information about insider trades with Natus Medical, click here.
Natus Medical reported revenue of $95.958 million in the second quarter. In the previous year’s second quarter, the company reported revenue of $91.937 million. Net income increased from $9.851 million, or 30 cents per share, to $10.512 million, or 32 cents per share, when comparing the same time periods. Hawkins commented that the company’s “neurodiagnostic and newborn care businesses reported record results in the second quarter.”
Hawkins also said the company remains “committed to achieving full-year 2016 non-GAAP operating margin goal of 20%.”
Natus Medical announced the appointment of Barbara R. Paul, M.D., to its board of directors on Sept. 22. Chairman Robert Gunst commented that Paul’s “significant medical and regulatory experience will complement the expertise” of current board members. Four days later, the company announced its entrance into a definitive agreement with GN Store Nord A/S (GN, Financial). Under the agreement, Natus will acquire the GN Otometrics business from GN Store Nord in a cash transaction of $145 million. GN Otometrics is a global manufacturer of hearing diagnostics and balance assessment equipment, disposables and software and has annual revenue of approximately $110 million. Hawkins commented that the addition of GN Otometrics may cause Natus revenue to reach a record high of $500 million in 2017. The transaction is expected to close by the end of the year.
According to GuruFocus.com, Natus Medical has a business predictability rank of 1 out of 5 stars. For more information about business predictability rank, click here.
Steven Cohen (Trades, Portfolio) and Joel Greenblatt (Trades, Portfolio) both increased their stakes in Natus Medical during the second quarter. Cohen acquired 622,600 shares of the company for an average per share price of $33.49 after selling out all 14,137 held shares of the company for an average per share price of $25.20 in the previous quarter. Greenblatt increased his stake in Natus by 231.17%, purchasing 195,483 shares after reducing his stake in the company every quarter since the first quarter of 2015. The total estimated gain of the holding since the fourth quarter of 2013 is 35%. For more information about guru transactions with Natus Medical, click here.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature.
Start a free seven-day trial of Premium Membership to GuruFocus.
